MOONLAKE IMMUNOTHERAPEUTICS Proceeds from Long-Term Debt Issued
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Proceeds from Long-Term Debt Issued of $24.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from issuance of long-term debt for the quarter ending 2026-06-30 was $0.00.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from issuance of long-term debt for the quarter ending 2026-03-31 was $24.47M, a 66.49% decline year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from issuance of long-term debt for the quarter ending 2025-12-31 was $0.00.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from issuance of long-term debt for the quarter ending 2025-09-30 was $0.00.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from issuance of long-term debt for fiscal 2025 was $73.02M.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from issuance of long-term debt for fiscal 2024 was $0.00.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from issuance of long-term debt for fiscal 2023 was $0.00.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $24.47M 10-Q · filed 2026-08-10 | $24.47M derived: sum of 3 quarters · filed 2026-08-10 | $24.47M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $24.47M 10-Q · filed 2026-05-11 | $24.47M derived: sum of 2 quarters · filed 2026-05-11 | $24.47M derived: sum of 3 quarters · filed 2026-05-11 | $24.47M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-08-10 | $73.02M 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-10 | $73.02M 10-Q · filed 2025-11-05 | $73.02M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $73.02M 10-Q · filed 2026-08-10 | $73.02M derived: sum of 3 quarters · filed 2026-08-10 | $73.02M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $73.02M 10-Q · filed 2026-05-11 | $73.02M derived: sum of 2 quarters · filed 2026-05-11 | $73.02M derived: sum of 3 quarters · filed 2026-05-11 | $73.02M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |